Amino Acid-Inducible Transgene Control in T and NK Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cellular immunotherapy methods, such as CAR-T cell and TCR transgenic T cell therapies, face challenges in controlling the therapeutic action and toxicity of reinjected cells, with issues like CAR exhaustion and toxicity, and there is a need for a flexible and reversible gene expression system to manage these cells effectively.
Innovation Solution
The NUTRIREG system uses a regulatory polynucleotide inducible by essential amino acid deficiency to control the expression of a transgene in human T or NK cells, leveraging the GCN2-ATF4 pathway to induce transgene expression only in activated cells through dietary amino acid deprivation, allowing reversible and controlled therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cells are used for cancer treatment, then anti-tumor efficacy is improved, but CAR exhaustion and toxicity occur reducing long-term therapeutic action
Solution Approach 1:
The patent applies dynamics by making the CAR-T cell system adjustable and reversible. The inducible expression system allows dynamic control of CAR protein levels in response to changing therapeutic needs, enabling the system to adapt from high expression (for efficacy) to low or zero expression (to prevent exhaustion and toxicity), thus extending long-term therapeutic action.
Solution Approach 2:
The patent changes the expression level parameter of the CAR gene dynamically. By using an inducible promoter system responsive to amino acid availability, the CAR protein expression can be upregulated when tumor targeting is needed and downregulated when exhaustion or toxicity occurs, resolving the contradiction between maintaining efficacy and preventing long-term degradation.
2Productivity
If transgene expression is continuously activated in T cells, then therapeutic action is enhanced, but toxicity increases
Solution Approach 1:
The patent implements periodic action through conditional transgene expression. The CAR-T cells express the therapeutic transgene only during specific periods when activated by amino acid deprivation signals, rather than continuously. This periodic expression pattern allows therapeutic action to be delivered when needed while avoiding constant toxicity accumulation.
Solution Approach 2:
The patent incorporates feedback control where the expression of the transgene responds to cellular metabolic state (amino acid availability). When cells experience stress or toxicity, amino acid metabolism changes, which automatically downregulates transgene expression through the inducible promoter, creating a self-regulating feedback mechanism that prevents excessive toxicity.
3Adaptability or versatility
If a gene expression regulation system is added to control T cell therapy, then controllability is improved, but device complexity increases
Solution Approach 1:
The patent applies self-service by designing a regulation system that uses the cell's own metabolic state to control transgene expression. The inducible promoter automatically responds to amino acid availability without requiring external control mechanisms, reducing system complexity while maintaining adaptability. The system serves itself by using endogenous metabolic signals as the control input.
4Duration of action of stationary object
If essential amino acid deficiency is used to induce transgene expression, then reversibility is improved, but ease of operation decreases
Solution Approach 1:
The patent replaces complex mechanical or chemical control systems with a biochemical substitution approach. Instead of using complex induction agents or mechanical switches, the system uses natural amino acid metabolism as the control mechanism. This substitution simplifies the overall system while maintaining reversibility, as amino acid supplementation is a simple physiological intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system enables precise and reversible regulation of transgene expression in activated T or NK cells, enhancing therapeutic efficacy while minimizing toxicity, applicable in treating cancers, autoimmune diseases, and allograft rejection.
Implementation Method 1
In case of lack, the organism must absolutely adapt, which is why it activates a specific signaling pathway, the GCN2-ATF4 pathway, leading to the overexpression of a transcription factor (ATF4) present in all the cells of the organism.
Implementation Method 2
This transcription factor will then bind to the DNA at the level of the promoter of specific target genes (Amino Acid Responsive—AARE sequences) and activate their transcription.
Data Source
AI summary
The present invention concerns a human T cell or NK cell comprising a nucleic acid construct which comprises a transgene which is placed under the control of a regulatory polynucleotide inducible by a deficiency in at least one essential amino acid. and cellular immunotherapy employing said human T cell or NK cell.